Johnson & Johnson Goodwill and Intangible Assets 2012-2026 | JNJ
Johnson & Johnson goodwill and intangible assets from 2012 to 2026. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Johnson & Johnson goodwill and intangible assets for the quarter ending March 31, 2026 were $99.175B, a 21.21% increase year-over-year.
- Johnson & Johnson goodwill and intangible assets for 2025 were $99.175B, a 21.21% increase from 2024.
- Johnson & Johnson goodwill and intangible assets for 2024 were $81.818B, a 15.67% increase from 2023.
- Johnson & Johnson goodwill and intangible assets for 2023 were $70.733B, a 5.1% decline from 2022.
|
Johnson & Johnson Annual Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2025 | $99,175 |
| 2024 | $81,818 |
| 2023 | $70,733 |
| 2022 | $74,536 |
| 2021 | $81,638 |
| 2020 | $89,795 |
| 2019 | $81,282 |
| 2018 | $78,064 |
| 2017 | $85,134 |
| 2016 | $49,681 |
| 2015 | $47,393 |
| 2014 | $49,054 |
| 2013 | $50,745 |
| 2012 | $51,176 |
| 2011 | $34,276 |
|
Johnson & Johnson Quarterly Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2025-12-31 | $99,175 |
| 2025-09-30 | $96,785 |
| 2025-06-30 | $97,952 |
| 2025-03-31 | $81,223 |
| 2024-12-31 | $81,818 |
| 2024-09-30 | $84,289 |
| 2024-06-30 | $83,975 |
| 2024-03-31 | $70,902 |
| 2023-12-31 | $70,733 |
| 2023-09-30 | $71,145 |
| 2023-06-30 | $91,686 |
| 2023-03-31 | $93,023 |
| 2022-12-31 | $74,536 |
| 2022-09-30 | $73,719 |
| 2022-06-30 | $76,574 |
| 2022-03-31 | $79,355 |
| 2021-12-31 | $81,638 |
| 2021-09-30 | $83,345 |
| 2021-06-30 | $86,063 |
| 2021-03-31 | $86,798 |
| 2020-12-31 | $89,795 |
| 2020-09-30 | $81,313 |
| 2020-06-30 | $81,303 |
| 2020-03-31 | $80,809 |
| 2019-12-31 | $81,282 |
| 2019-09-30 | $81,137 |
| 2019-06-30 | $82,993 |
| 2019-03-31 | $78,348 |
| 2018-12-31 | $78,064 |
| 2018-09-30 | $79,339 |
| 2018-06-30 | $80,402 |
| 2018-03-31 | $83,514 |
| 2017-12-31 | $85,134 |
| 2017-09-30 | $85,877 |
| 2017-06-30 | $86,176 |
| 2017-03-31 | $54,310 |
| 2016-12-31 | $49,681 |
| 2016-09-30 | $50,813 |
| 2016-06-30 | $47,798 |
| 2016-03-31 | $47,688 |
| 2015-12-31 | $47,393 |
| 2015-09-30 | $47,267 |
| 2015-06-30 | $48,510 |
| 2015-03-31 | $48,370 |
| 2014-12-31 | $49,054 |
| 2014-09-30 | $47,940 |
| 2014-06-30 | $49,111 |
| 2014-03-31 | $49,821 |
| 2013-12-31 | $50,745 |
| 2013-09-30 | $51,319 |
| 2013-06-30 | $50,041 |
| 2013-03-31 | $50,358 |
| 2012-12-31 | $51,176 |
| 2012-09-30 | $50,567 |
| 2012-06-30 | $50,611 |
| 2012-03-31 | $34,496 |
| 2011-12-31 | $34,276 |
| 2011-09-30 | $34,274 |
| 2011-06-30 | $34,621 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |